Reagents and methods for treating cancer and autoimmune disease
AssigneeUniversity of Connecticut
InventorLaijun Lai
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for treating cancer by administering to a subject having cancer antibodies against one or more of CD300c, BTN5 (Erythroid membrane-associated protein), TAPBPL (antigen processing (TAP) binding protein like protein), Skint8 (selection and upkeep of intraepithelial T cells 8 protein), and CD300f. Also disclosed herein are methods for treating autoimmune diseases by administering to a subject having an autoimmune disease an IgV domain, or a nucleic acid encoding an IgV domain, from one or more of CD300c, BTN5, TAPBPL, SkintS, and CD300f. Also disclosed herein are antibodies against CD300c and TAPBPL, and fusion proteins that can be used in the methods for treating autoimmune disease.
Claims19
An isolated anti-human CD300c antibody, or fragment thereof, comprising each of the following complementarity determining regions (CDRs):
- Heavy chain CDR1 (H-CDR1) comprising the amino acid sequence IYGMN (SEQ ID NO:
- 10);
- Heavy chain CDR2 (H-CDR2) comprising the amino acid sequence WINTYT (SEQ ID NO:
- 11);
- Heavy chain CDR3 (H-CDR3) comprising the amino acid sequence ARSRFAY (SEQ ID NO:
- 12);
- Light chain CDR1 (L-CDR1) comprising the amino acid sequence KASQNVGTNVA (SEQ ID NO:
- 13);
- Light chain CDR2 (L-CDR2) comprising the amino acid sequence SASYRYS (SEQ ID NO:14);
- and
- Light chain CDR3 (L-CDR3) comprising the amino acid sequence QQYNSYPLT (SEQ ID NO:15).
A method for treating colon cancer or a melanoma, comprising administering to a subject in need thereof an antibody that selectively binds to an extracellular domain (ECD) of human CD300c, in an amount effective to treat the colon cancer or melanoma, wherein the antibody comprises each of the following complementarity determining regions (CDRs):
- Heavy chain CDR1 (H-CDR1) comprising the amino acid sequence IYGMN (SEQ ID NO:
- 10);
- Heavy chain CDR2 (H-CDR2) comprising the amino acid sequence WINTYT (SEQ ID NO:
- 11);
- Heavy chain CDR3 (H-CDR3) comprising the amino acid sequence ARSRFAY (SEQ ID NO:
- 12);
- Light chain CDR1 (L-CDR1) comprising the amino acid sequence KASQNVGTNVA (SEQ ID NO:
- 13);
- Light chain CDR2 (L-CDR2) comprising the amino acid sequence SASYRYS (SEQ ID NO:14);
- and
- Light chain CDR3 (L-CDR3) comprising the amino acid sequence QQYNSYPLT (SEQ ID NO:15).
Dependencies are inferred from the claim text.